Cargando…

A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells

BACKGROUND: Evodiamine has gained wide interests recently because of its antitumor activities. However, a superior bioavailability is required to achieve better efficacy due to its poor water solubility. The aim of this study was to enhance the evodiamine’s aqueous solubility by preparing evodiamine...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Chao, Gao, Li-Na, Yan, Kuo, Cui, Yuan-Lu, Zhang, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959055/
https://www.ncbi.nlm.nih.gov/pubmed/27458481
http://dx.doi.org/10.1186/s13065-016-0191-y
_version_ 1782444364618792960
author Qiu, Chao
Gao, Li-Na
Yan, Kuo
Cui, Yuan-Lu
Zhang, Ye
author_facet Qiu, Chao
Gao, Li-Na
Yan, Kuo
Cui, Yuan-Lu
Zhang, Ye
author_sort Qiu, Chao
collection PubMed
description BACKGROUND: Evodiamine has gained wide interests recently because of its antitumor activities. However, a superior bioavailability is required to achieve better efficacy due to its poor water solubility. The aim of this study was to enhance the evodiamine’s aqueous solubility by preparing evodiamine/hydroxypropyl-β-cyclodextrin (EVO/HP-β-CD) inclusion complex, which is incorporated evodiamine into HP-β-CD, and compare the antitumor activities before and after inclusion with HP-β-CD in human hepatoma HepG2 cells. RESULTS: The EVO/HP-β-CD inclusion complexes were prepared by the kneading method and structurally characterized. P-glycoprotein ATPase assays firstly demonstrated that evodiamine was a substrate of P-glycoprotein, while HP-β-CD and EVO/HP-β-CD inclusion complexes inhibited P-glycoprotein by blocking P-glycoprotein ATPase activity. The EVO/HP-β-CD inclusion complexes may be a promising anticancer drug candidate without drug resistance. After given evodiamine or EVO/HP-β-CD inclusion complexes intervention, cell viability evaluation indicated that the half inhibition concentration of evodiamine and EVO/HP-β-CD inclusion complexes on HepG2 cells was 8.516 and 0.977 μM, respectively. The caspase-3 enzyme activity analysis and Annexin V/PI double-staining revealed that EVO/HP-β-CD inclusion complexes possessed better antitumor activities than evodiamine. Additionally, Hoechst 33258 staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay demonstrated that EVO/HP-β-CD inclusion complexes induced HepG2 cell apoptosis more effectively than evodiamine. CONCLUSIONS: The improved antitumor activities of evodiamine were attributed to the enhanced solubility and P-glycoprotein inhibition by HP-β-CD. These results are promising for the drug administration of EVO/HP-β-CD inclusion complexes to enhance the bioavailability of evodiamine in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13065-016-0191-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4959055
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-49590552016-07-26 A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells Qiu, Chao Gao, Li-Na Yan, Kuo Cui, Yuan-Lu Zhang, Ye Chem Cent J Research Article BACKGROUND: Evodiamine has gained wide interests recently because of its antitumor activities. However, a superior bioavailability is required to achieve better efficacy due to its poor water solubility. The aim of this study was to enhance the evodiamine’s aqueous solubility by preparing evodiamine/hydroxypropyl-β-cyclodextrin (EVO/HP-β-CD) inclusion complex, which is incorporated evodiamine into HP-β-CD, and compare the antitumor activities before and after inclusion with HP-β-CD in human hepatoma HepG2 cells. RESULTS: The EVO/HP-β-CD inclusion complexes were prepared by the kneading method and structurally characterized. P-glycoprotein ATPase assays firstly demonstrated that evodiamine was a substrate of P-glycoprotein, while HP-β-CD and EVO/HP-β-CD inclusion complexes inhibited P-glycoprotein by blocking P-glycoprotein ATPase activity. The EVO/HP-β-CD inclusion complexes may be a promising anticancer drug candidate without drug resistance. After given evodiamine or EVO/HP-β-CD inclusion complexes intervention, cell viability evaluation indicated that the half inhibition concentration of evodiamine and EVO/HP-β-CD inclusion complexes on HepG2 cells was 8.516 and 0.977 μM, respectively. The caspase-3 enzyme activity analysis and Annexin V/PI double-staining revealed that EVO/HP-β-CD inclusion complexes possessed better antitumor activities than evodiamine. Additionally, Hoechst 33258 staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay demonstrated that EVO/HP-β-CD inclusion complexes induced HepG2 cell apoptosis more effectively than evodiamine. CONCLUSIONS: The improved antitumor activities of evodiamine were attributed to the enhanced solubility and P-glycoprotein inhibition by HP-β-CD. These results are promising for the drug administration of EVO/HP-β-CD inclusion complexes to enhance the bioavailability of evodiamine in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13065-016-0191-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-07-25 /pmc/articles/PMC4959055/ /pubmed/27458481 http://dx.doi.org/10.1186/s13065-016-0191-y Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Qiu, Chao
Gao, Li-Na
Yan, Kuo
Cui, Yuan-Lu
Zhang, Ye
A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
title A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
title_full A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
title_fullStr A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
title_full_unstemmed A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
title_short A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
title_sort promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma hepg2 cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959055/
https://www.ncbi.nlm.nih.gov/pubmed/27458481
http://dx.doi.org/10.1186/s13065-016-0191-y
work_keys_str_mv AT qiuchao apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT gaolina apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT yankuo apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT cuiyuanlu apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT zhangye apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT qiuchao promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT gaolina promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT yankuo promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT cuiyuanlu promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells
AT zhangye promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells